Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Verrica Pharmaceuticals (VRCA) Accumulated Depreciation & Amortization (2021 - 2025)

Verrica Pharmaceuticals has reported Accumulated Depreciation & Amortization over the past 5 years, most recently at $1.0 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $1.0 million for Q4 2025, down 16.53% from a year ago — trailing twelve months through Dec 2025 was $1.0 million (down 16.53% YoY), and the annual figure for FY2025 was $1.0 million, down 16.53%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $1.0 million at Verrica Pharmaceuticals, up from $1.0 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for VRCA hit a ceiling of $1.3 million in Q1 2025 and a floor of $113000.0 in Q3 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $999500.0 (2023), compared with a mean of $814400.0.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: surged 403.54% in 2022 and later fell 18.26% in 2025.
  • Verrica Pharmaceuticals' Accumulated Depreciation & Amortization stood at $254000.0 in 2021, then skyrocketed by 175.2% to $699000.0 in 2022, then skyrocketed by 67.95% to $1.2 million in 2023, then increased by 7.16% to $1.3 million in 2024, then dropped by 16.53% to $1.0 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $1.0 million (Q4 2025), $1.0 million (Q3 2025), and $1.1 million (Q2 2025) per Business Quant data.